Global Cancer Biological Therapy Market Expected To Expand At 6.7% CAGR During 2019–2025

As per the analysis by the Zion Market Research experts, the valuation of the global cancer biological therapy market was around USD 69.7 billion in 2018 and is anticipated to observe a CAGR of around 6.7% from 2019 to 2025. A few of the key market players active in the cancer biological therapy market consist of Amgen, AbbVie, AstraZeneca, Astellas, Celgene Corporation, Bayer, ELI Lilly & Company, Eisai, GlaxoSmithKline, F. Hoffmann-La Roche, Merck, Incyte, Otsuka, Novartis, Sanofi, Pfizer, Spectrum Pharmaceuticals, Takeda Pharmaceuticals, and Seattle Genetics. The market players mainly set their efforts on adopting numerous strategic approaches such as acquisition, mergers, and new product launches, which assist them in reinforcing their prevailing market status. To cite, acquirement of an oncology-focused biopharmaceutical firm, TESARO, was declared by GlaxoSmithKline in Dec 2018. This purchase will assist the firm to improve its oncology business and promote the growth of the firm.

Increasing Cancer Prevalence Globally Anticipated To Boost The Market Growth

The increasing incidence of cancer across the globe is the major factor that will boost the global cancer biological therapy market in the coming years. Growing consumption of tobacco and alcohol has resulted in an increase in the global cancer burden, thus boosting the expansion of the global cancer biological therapy market. Further, the rising investments in R&D activities by the major market players will add to the growth of the industry in the coming period. In addition, the mounting alertness about cancer and rising healthcare expenditure has aroused demand for efficient cancer treatment. Also, technological developments in oncology are expected to fuel the market growth during the forecast period.

By Product, Vaccine Segment Of The Market Expected To Witness Substantial Growth

Vaccines segment of the global cancer biological therapy market is projected to observe substantial growth in the coming period on account of growing cancer prevalence across the world together with increasing alertness about cancer preventive measures. Also, the rising need for preventive vaccines like hepatitis B vaccines (HBV) and human papilloma vaccines (HPV) will boost the segmental growth.

North America Likely To Continue Its Dominance During The Forecast Period

In 2018, the global cancer biological therapy market was lead by North America and is anticipated to continue its supremacy with significant expansion during the forecast period. This regional market is expected to be boosted by factors such as increasing cancer incidences in the region together with the rising elderly population. Europe cancer biological therapy market is also projected to display a considerable growth rate owing to the rising cancer burden in the region, progresses in cancer therapies, and the existence of a huge aged patient pool.

Browse the full “Global Cancer Biological Therapy Market - By Application (Diagnostic Laboratories, Hospitals, Pharmaceutical & Biotechnology Companies, And Research & Academic Laboratories), By Product (Vaccines {Therapeutic Vaccines And Preventive Vaccines}, Monoclonal Antibodies { Conjugated Monoclonal Antibodies, Naked Monoclonal Antibodies, And Bispecific Monoclonal Antibodies}, Blood Cell Growth Factors {Filgrastim And Lenograstim}, Cancer Growth Blockers { Proteasome Inhibitors, Tyrosine Kinase Inhibitors, And mTOR Inhibitors}, Cytokine { Interleukin And Interferon}), And By Region - Global Industry Perspective, Comprehensive Analysis, and Forecast, 2020 – 2026.” Report at https://www.zionmarketresearch.com/report/cancer-biological-therapy-market

The global cancer biological therapy market is segmented as follows:

By product type

• Monoclonal Antibodies
  • Naked Monoclonal Antibodies
  • Conjugated Monoclonal Antibodies
  • Bispecific Monoclonal Antibodies
• Vaccines
  • Preventive Vaccines
  • Therapeutic Vaccines
• Cancer Growth Blockers
  • Tyrosine Kinase Inhibitors
  • Proteasome Inhibitors
  • mTOR Inhibitors
• Blood Cell Growth Factors
  • Lenograstim
  • Filgrastim
• Cytokine
  • Interferon
  • Interleukin

By Application:

• Hospitals
• Diagnostic Laboratories
• Research & Academic Laboratories
• Pharmaceutical & Biotechnology Companies

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:

Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com